Exacerbation of Idiopathic Interstitial Pneumonias Associated with Lung Cancer Therapy

Minegishi, Yuji; Takenaka, Kiyoshi; Mizutani, Hideki; Sudoh, Junko; Noro, Rintaro; Okano, Toshio; Azuma, Arata; Yoshimura, Akinobu; Ando, Masahiro; Tsuboi, Eitaka; Kudoh, Shoji; Gemma, Akihiko

doi:10.2169/internalmedicine.48.1650

Cited by 118 publications

(103 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Acute lung injury can occur in patients undergoing surgery, thoracic radiotherapy, or cytotoxic or molecular-targeted therapy [54,55] . Although this complication seems to be more frequent in Japanese patients than in patients from other countries, the precise epidemiology and underlying mechanisms are not well known.…”

Section: Putative Lung Stem Cells Activated By Chronic Inflammation Imentioning

confidence: 99%

Chronic obstructive pulmonary disease as a risk factor for lung cancer

Takiguchi

Sekine

Iwasawa

et al. 2014

WJCO

View full text Add to dashboard Cite

The association between chronic obstructive pulmonary disease (COPD) and lung cancer has long been a subject of intense debate. The high prevalence of COPD in elderly smokers inevitably strengthens their coincidence. In addition to this contingent coincidence, recent studies have revealed a close association between the two diseases that is independent of the smoking history; that is, the existence of COPD is an independent risk factor for the development of lung cancer. Molecular-based evidence has been accumulating as a result of the efforts to explain the underlying mechanisms of this association. These mechanisms may include the following: the retention of airborne carcinogens followed by the activation of oncogenes and the suppression of tumor suppressor genes; the complex molecular mechanism associated with chronic inflammation in the distal airways of patients with COPD; the possible involvement of putative distal airway stem cells; and genetic factors that are common to both COPD and lung cancer. The existence of COPD in patients with lung cancer may potentially affect the process of diagnosis, surgical resection, radiotherapy, chemotherapy, and end-of-life care. The comprehensive management of COPD is extremely important for the appropriate treatment of lung cancer. Surgical resections with the aid of early interventions for COPD are often possible, even for patients with mild-to-moderate COPD. New challenges, such as lung cancer CT screening for individuals at high risk, are now in the process of being implemented. Evaluating the risk of lung cancer in patients with COPD may be warranted in community-based lung cancer screening.

show abstract

Section: Putative Lung Stem Cells Activated By Chronic Inflammation Imentioning

confidence: 99%

Chronic obstructive pulmonary disease as a risk factor for lung cancer

Takiguchi

Sekine

Iwasawa

et al. 2014

WJCO

View full text Add to dashboard Cite

show abstract

“…The median survival was 3.5 years for patients with an oncogenic driver and genotype-directed therapy, compared with 2.4 years for those with any oncogenic driver(s) who did not receive genotype-directed therapy. By contrast, patients with severe complications, such as ILD, are excluded from a number of clinical trials, as pre-existing ILD is a risk factor for the NSCLC therapy related to ILD (10,11).…”

Section: Introductionmentioning

confidence: 99%

“…ILD, particularly idiopathic pulmonary fibrosis (IPF), is a frequent complication in patients with NSCLC (13), and the incidence of lung cancer in patients with ILD is 20-30% (11). Approximately 10% of the patients with ILD reported acute exacerbations (AE) generally characterized by suddenly progressive and severe respiratory failure, accompanied by new lung opacities and diffuse alveolar damage (14).…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease

Niwa

Nakahara

Yokoba

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. There are few established treatments for patients with non-small-cell lung cancer (NSCLC) with interstitial lung disease (ILD). The safety and efficacy of albumin-bound paclitaxel (nab-paclitaxel) in combination with carboplatin is uncertain, although the combination of carboplatin and paclitaxel is the most common regimen for treating NSCLC patients with ILD. A total of 9 NSCLC patients with ILD, treated between April 2013 and March 2016, were retrospectively investigated. Carboplatin (AUC 5-6) was administered on day 1 and nab-paclitaxel on days 1, 8 and 15, every 4-6 weeks. The median age of the patients upon initiating chemotherapy was 67 years. The pathological examination revealed 6 patients with squamous cell carcinoma, and 6 patients exhibited the typical pattern of ILD. The response rate was 55.6%, and the median progression-free and overall survival time was 174 and 344 days, respectively. Acute exacerbation of ILD was not observed in any of the patients, and febrile neutropenia developed in 3 patients (3/9, 33.3%). Thus, treatment with carboplatin plus nab-paclitaxel was found to be safe and effective for NSCLC patients with ILD, although management of hematological adverse events, such as febrile neutropenia, was required. However, these encouraging results require confirmation by a large-scale clinical trial.

show abstract

“…A UIP pattern on CT was reported to be a risk factor for chemotherapy-induced acute exacerbation of ILD (1,11,14). Another report demonstrated that lower forced vital capacity is a risk factor, but a UIP pattern is not (4).…”

Section: Discussionmentioning

confidence: 99%

“…One of the most effective treatments for lung cancer with ILD is the combination of platinum agents with paclitaxel or etoposide (1). The incidence rate of acute exacerbation of ILD in patients treated with weekly paclitaxel in combination with carboplatin was reported to be 5.6-27% (2-4).…”

Section: Introductionmentioning

confidence: 99%

Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease

Yasuda

Nomizo

Ozasa

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Lung cancer with preexisting interstitial lung disease (ILD) is difficult to treat due to the risk of acute exacerbation of ILD. Nanoparticle albumin-bound (nab-) paclitaxel improves the overall response rate and reduces neuropathy more efficiently compared with conventional solvent-based (sb-) paclitaxel in patients with advanced non-small-cell lung cancer. However, it is not known whether the risk of acute exacerbation of ILD with nab-paclitaxel is higher compared with that with sb-paclitaxel. Advanced lung cancer patients with ILD treated with nab-paclitaxel (n=14) or sb-paclitaxel (n=14) were retrospectively reviewed. Acute exacerbation of ILD developed in 1/14 patients (7.7%) receiving nab-paclitaxel and 3/14 patients (21.4%) receiving sb-paclitaxel; the difference was not statistically significant. To the best of our knowledge, this is the first study to compare the incidence of acute exacerbation of ILD with nab-paclitaxel with that of sb-paclitaxel in patients with advanced lung cancer with preexisting ILD. The results of the present study support conducting a prospective clinical trial to confirm the clinical benefit of this agent.

show abstract

Exacerbation of Idiopathic Interstitial Pneumonias Associated with Lung Cancer Therapy

Abstract: Objective and Methods Idiopathic interstitial pneumonias (IIPs)

Cited by 118 publications

References 30 publications

Chronic obstructive pulmonary disease as a risk factor for lung cancer

Chronic obstructive pulmonary disease as a risk factor for lung cancer

Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease

Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease

Contact Info

Product

Resources

About